WO2008030260A3 - Treatment of variola viral infections using a tissue factor inhibitor - Google Patents
Treatment of variola viral infections using a tissue factor inhibitor Download PDFInfo
- Publication number
- WO2008030260A3 WO2008030260A3 PCT/US2006/049186 US2006049186W WO2008030260A3 WO 2008030260 A3 WO2008030260 A3 WO 2008030260A3 US 2006049186 W US2006049186 W US 2006049186W WO 2008030260 A3 WO2008030260 A3 WO 2008030260A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variola
- treatment
- viral infections
- tissue factor
- factor inhibitor
- Prior art date
Links
- 208000001203 Smallpox Diseases 0.000 title abstract 2
- 102000002262 Thromboplastin Human genes 0.000 title abstract 2
- 108010000499 Thromboplastin Proteins 0.000 title abstract 2
- 241000870995 Variola Species 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 241000700647 Variola virus Species 0.000 abstract 1
- 208000005871 monkeypox Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides novel methods for the treatment of variola viral infections, such as smallpox and monkeypox, by administering a tissue factor inhibitor.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75297205P | 2005-12-22 | 2005-12-22 | |
US60/752,972 | 2005-12-22 | ||
US75805706P | 2006-01-11 | 2006-01-11 | |
US60/758,057 | 2006-01-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008030260A2 WO2008030260A2 (en) | 2008-03-13 |
WO2008030260A3 true WO2008030260A3 (en) | 2008-06-26 |
Family
ID=38218698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/049185 WO2007076091A2 (en) | 2005-12-22 | 2006-12-21 | Treatment of viral infections using a tissue factor inhibitor |
PCT/US2006/049186 WO2008030260A2 (en) | 2005-12-22 | 2006-12-21 | Treatment of variola viral infections using a tissue factor inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/049185 WO2007076091A2 (en) | 2005-12-22 | 2006-12-21 | Treatment of viral infections using a tissue factor inhibitor |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2007076091A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
NO2582728T3 (en) | 2010-06-15 | 2018-01-20 | ||
EP3235822B1 (en) | 2014-12-19 | 2020-01-29 | Nagasaki University | Novel bisphosphonic acid derivative and application for same |
US10430534B2 (en) * | 2016-11-30 | 2019-10-01 | Numem Inc. | Resistance-based memory compiler |
TWI841554B (en) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
WO2021188864A1 (en) * | 2020-03-19 | 2021-09-23 | Eumentis Therapeutics, Inc. | Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections |
CN118772282A (en) * | 2023-04-10 | 2024-10-15 | 复旦大学 | Preparation method and use of nanoantibodies and conjugates targeting tissue factor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274142B1 (en) * | 1986-11-04 | 2001-08-14 | Genentech, Inc. | Methods of neutralizing coagulation with anti-tissue factor antibodies |
US20020168357A1 (en) * | 1997-03-10 | 2002-11-14 | Hing C. Wong | Antibodies for inhibiting blood coagulation and methods of use thereof |
US6593291B1 (en) * | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
US6849617B2 (en) * | 1999-10-27 | 2005-02-01 | Sunol Molecular Corporation | Tissue factor antagonists and methods of use thereof |
US20050158325A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7749498B2 (en) * | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20050169927A1 (en) * | 2001-10-02 | 2005-08-04 | Novo Nordisk A/S | Human tissue factor antibodies |
US7132398B2 (en) * | 2003-05-06 | 2006-11-07 | Dendreon Corporation | Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
-
2006
- 2006-12-21 WO PCT/US2006/049185 patent/WO2007076091A2/en active Application Filing
- 2006-12-21 WO PCT/US2006/049186 patent/WO2008030260A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274142B1 (en) * | 1986-11-04 | 2001-08-14 | Genentech, Inc. | Methods of neutralizing coagulation with anti-tissue factor antibodies |
US6593291B1 (en) * | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
US20020168357A1 (en) * | 1997-03-10 | 2002-11-14 | Hing C. Wong | Antibodies for inhibiting blood coagulation and methods of use thereof |
US6849617B2 (en) * | 1999-10-27 | 2005-02-01 | Sunol Molecular Corporation | Tissue factor antagonists and methods of use thereof |
US20050158325A1 (en) * | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Immunomodulatory combinations |
Also Published As
Publication number | Publication date |
---|---|
WO2008030260A2 (en) | 2008-03-13 |
WO2007076091A2 (en) | 2007-07-05 |
WO2007076091A3 (en) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
WO2008115281A3 (en) | Compounds for treating viral infections | |
MX2009013829A (en) | Therapeutic compositions and the use thereof. | |
WO2006124713A3 (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
TN2010000137A1 (en) | Spiropyrrolidines and their use against hcv and hiv infection | |
WO2009105513A8 (en) | Novel compounds and methods for therapy | |
EP1865967A4 (en) | Compounds, compositions and methods for the treatment of viral infections and other medical disorders | |
AP2212A (en) | Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. | |
WO2007084413A3 (en) | Methods for treating hepatitis c | |
HK1113085A1 (en) | Compounds, compositions and methods for the treatment of poxvirus infections | |
WO2007084435A3 (en) | Methods for treating hepatitis c | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2005115398A3 (en) | Hiv integrase inhibitors | |
MX2010001733A (en) | Imidazopyrazine compounds. | |
WO2008030260A3 (en) | Treatment of variola viral infections using a tissue factor inhibitor | |
MX2009013828A (en) | Therapeutic compositions and the use thereof. | |
WO2007047608A3 (en) | Fibrin targeted therapeutics | |
AU2005235116A1 (en) | Combinations for treating HIV infection | |
WO2009111633A3 (en) | Mercaptan and seleno-mercaptan compounds and methods of using them | |
WO2005086836A3 (en) | Ion channel modulators | |
WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
WO2010095041A3 (en) | Compositions, methods, and kits for treating influenza viral infections | |
WO2007005620A3 (en) | Arginase ii: a target treatment of aging heart and heart failure | |
WO2005086895A3 (en) | Ion channel modulators | |
PT2366393E (en) | Roflumilast for the treatment of pulmonary hypertension |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06851593 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06851593 Country of ref document: EP Kind code of ref document: A2 |